Equities Analysts Offer Predictions for INSP FY2027 Earnings

Inspire Medical Systems, Inc. (NYSE:INSP) – Investment analysts at Leerink Partnrs decreased their FY2027 earnings per share (EPS) estimates for shares of Inspire Medical Systems in a research report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings of $3.57 per share for the year, down from their prior forecast of $3.63. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $1.33 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems’ FY2028 earnings at $5.69 EPS.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, November 4th. The company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.06 by $0.54. The company had revenue of $203.20 million for the quarter, compared to the consensus estimate of $197.59 million. Inspire Medical Systems had a net margin of 4.37% and a return on equity of 5.30%. The firm’s revenue for the quarter was up 32.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.29) earnings per share.

INSP has been the topic of several other reports. Robert W. Baird raised their target price on Inspire Medical Systems from $240.00 to $252.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Stifel Nicolaus reiterated a “hold” rating and issued a $200.00 price objective (up from $170.00) on shares of Inspire Medical Systems in a research report on Tuesday, November 5th. Bank of America upgraded Inspire Medical Systems from a “neutral” rating to a “buy” rating and upped their target price for the company from $220.00 to $255.00 in a report on Wednesday, November 20th. Wells Fargo & Company raised their price target on Inspire Medical Systems from $187.00 to $198.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $260.00 price objective on shares of Inspire Medical Systems in a research report on Tuesday, November 5th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $233.58.

Inspire Medical Systems Trading Up 2.5 %

INSP stock opened at $193.85 on Tuesday. The stock has a market capitalization of $5.81 billion, a price-to-earnings ratio of 181.17 and a beta of 1.36. The firm’s 50-day moving average price is $198.72 and its two-hundred day moving average price is $175.85. Inspire Medical Systems has a 12-month low of $123.00 and a 12-month high of $257.40.

Hedge Funds Weigh In On Inspire Medical Systems

Several large investors have recently modified their holdings of INSP. State Street Corp raised its holdings in Inspire Medical Systems by 78.0% in the 3rd quarter. State Street Corp now owns 1,049,784 shares of the company’s stock worth $221,557,000 after acquiring an additional 459,990 shares during the last quarter. Point72 Asset Management L.P. raised its stake in shares of Inspire Medical Systems by 954.4% in the third quarter. Point72 Asset Management L.P. now owns 319,364 shares of the company’s stock worth $67,402,000 after purchasing an additional 289,075 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Inspire Medical Systems by 798.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 267,852 shares of the company’s stock valued at $56,530,000 after purchasing an additional 238,034 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Inspire Medical Systems by 32.3% during the second quarter. Bank of New York Mellon Corp now owns 787,815 shares of the company’s stock valued at $105,433,000 after buying an additional 192,238 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Inspire Medical Systems by 51.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 459,766 shares of the company’s stock worth $98,754,000 after buying an additional 156,893 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Insider Activity at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 800 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $220.00, for a total value of $176,000.00. Following the sale, the director now directly owns 23,140 shares of the company’s stock, valued at approximately $5,090,800. This represents a 3.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.10% of the stock is currently owned by corporate insiders.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.